NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7
Mechanism of Action
12.1. Mechanism of Action Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates…
Pharmacologic Class:
Vasoconstrictor
Clinical Trials (5)
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
Started Jul 2024
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
Started May 2009
123 enrolled
Heart Failure
Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)
Started Dec 2004
25 enrolled
Hypertension
Angiotensin II Blockade for Chronic Allograft Nephropathy
Started Dec 2002
153 enrolled
Kidney DiseaseProteinuria
Angiotensin II Antagonism of TGF-Beta 1
Started Aug 2002
36 enrolled
Diabetic NephropathyHypertension
Loss of Exclusivity
LOE Date
Jan 6, 2037
132 months away
Patent Expiry
Jan 6, 2037